• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高 Ki-67 表达预测滤泡性淋巴瘤 24 个月内疾病进展的风险因素和微环境。

High Ki-67 Expression Predicting a Risk Factor for the Progression of Disease within 24 Months and Microenvironment in Follicular Lymphoma.

机构信息

Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8666, Japan.

Department of Pathology and Laboratory Medicine, Showa University School of Medicine, Tokyo 142-8666, Japan.

出版信息

Int J Mol Sci. 2024 Oct 15;25(20):11057. doi: 10.3390/ijms252011057.

DOI:10.3390/ijms252011057
PMID:39456838
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11507466/
Abstract

Most follicular lymphomas (FLs) demonstrate an indolent clinical course with favorable outcomes; however, a fraction of patients experiences progression of disease within 24 months (POD24) and has adverse outcomes. This study aimed to determine the predictive risk factors for POD24 in patients with FL, and the characteristics of the microenvironment in FL with POD24. By multivariate analysis, we revealed that increased Ki-67 expression was associated with POD24 events in patients with FL (hazard ratio [HR]: 6.29, 95% confidence interval [CI]: 1.96-20.22, = 0.0020). Additionally, patients with FL with POD24 demonstrated immune cell reduction by immunohistochemistry analysis. Our results help better understand the therapeutic strategies for FL with POD24.

摘要

大多数滤泡性淋巴瘤（FL）表现出惰性的临床过程和良好的预后；然而，一部分患者在 24 个月内（POD24）疾病进展，并出现不良结局。本研究旨在确定滤泡性淋巴瘤患者 POD24 的预测风险因素，以及 POD24 滤泡性淋巴瘤的微环境特征。通过多变量分析，我们发现 Ki-67 表达增加与滤泡性淋巴瘤患者的 POD24 事件相关（风险比 [HR]：6.29，95%置信区间 [CI]：1.96-20.22， = 0.0020）。此外，POD24 滤泡性淋巴瘤患者的免疫细胞通过免疫组化分析显示减少。我们的研究结果有助于更好地理解 POD24 滤泡性淋巴瘤的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebae/11507466/c5102c6dadb0/ijms-25-11057-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebae/11507466/09f062e4ebc5/ijms-25-11057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebae/11507466/af64e24d2c6f/ijms-25-11057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebae/11507466/c5102c6dadb0/ijms-25-11057-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebae/11507466/09f062e4ebc5/ijms-25-11057-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebae/11507466/af64e24d2c6f/ijms-25-11057-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebae/11507466/c5102c6dadb0/ijms-25-11057-g003.jpg

相似文献

1
High Ki-67 Expression Predicting a Risk Factor for the Progression of Disease within 24 Months and Microenvironment in Follicular Lymphoma.高 Ki-67 表达预测滤泡性淋巴瘤 24 个月内疾病进展的风险因素和微环境。
Int J Mol Sci. 2024 Oct 15;25(20):11057. doi: 10.3390/ijms252011057.
2
Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.利用单细胞成像质谱流式细胞术揭示 24 个月内进展的滤泡性淋巴瘤患者肿瘤免疫微环境的演变。
J Hematol Oncol. 2022 Aug 22;15(1):115. doi: 10.1186/s13045-022-01326-z.
3
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.2 年内疾病进展（POD24）是识别真实世界中滤泡性淋巴瘤高危患者的一个有临床意义的终点。
Ann Hematol. 2020 Jul;99(7):1595-1604. doi: 10.1007/s00277-020-04025-2. Epub 2020 May 16.
4
Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.既往未经治疗的滤泡性淋巴瘤患者24个月无进展生存的危险因素：一项系统评价和Meta分析
Ann Hematol. 2022 Nov;101(11):2383-2392. doi: 10.1007/s00277-022-04914-8. Epub 2022 Aug 27.
5
Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration.在 24 个月内滤泡性淋巴瘤的疾病进展与肿瘤内免疫浸润减少有关。
J Clin Oncol. 2019 Dec 1;37(34):3300-3309. doi: 10.1200/JCO.18.02365. Epub 2019 Aug 28.
6
EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.EZH2 在滤泡性淋巴瘤中的表达是可变的，并且在首次治疗后 24 个月内与疾病的进展无关。
Anticancer Res. 2020 Dec;40(12):6685-6697. doi: 10.21873/anticanres.14692.
7
Good prognosis for follicular lymphoma with estrogen receptor α-positive follicular dendritic cells.雌激素受体α阳性滤泡树突细胞滤泡淋巴瘤预后良好。
Hematol Oncol. 2020 Aug;38(3):293-300. doi: 10.1002/hon.2730. Epub 2020 Apr 13.
8
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.临床遗传风险模型可预测滤泡性淋巴瘤一线免疫化疗后的早期进展。
Blood. 2016 Aug 25;128(8):1112-20. doi: 10.1182/blood-2016-05-717355. Epub 2016 Jul 14.
9
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.分析接受利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松作为一线治疗的患者 2 年内疾病进展和组织学转化的风险因素：JCOG0203 中晚期滤泡性淋巴瘤患者的 15 年随访。
Hematol Oncol. 2024 May;42(3):e3272. doi: 10.1002/hon.3272.
10
Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.T 细胞相关免疫标志物表达降低预示滤泡性淋巴瘤患者预后不良。
Cancer Sci. 2022 Feb;113(2):660-673. doi: 10.1111/cas.15224. Epub 2021 Dec 5.

引用本文的文献

1
Prognostication of Follicular Lymphoma: A Review of Prognostic Scores and Factors.滤泡性淋巴瘤的预后评估：预后评分与因素综述
Diagnostics (Basel). 2025 Mar 6;15(5):647. doi: 10.3390/diagnostics15050647.

本文引用的文献

1
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients.多组学分析滤泡性淋巴瘤揭示高危患者组织结构改变和基质重塑增强。
Cancer Cell. 2024 Mar 11;42(3):444-463.e10. doi: 10.1016/j.ccell.2024.02.001. Epub 2024 Feb 29.
2
A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.一种用于评估和靶向滤泡性淋巴瘤肿瘤免疫微环境的人淋巴瘤类器官模型。
Cell Stem Cell. 2024 Mar 7;31(3):410-420.e4. doi: 10.1016/j.stem.2024.01.012. Epub 2024 Feb 22.
3
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities.
多模态和空间分辨分析鉴定出结内 B 细胞淋巴瘤实体中 T 细胞浸润的不同模式。
Nat Cell Biol. 2024 Mar;26(3):478-489. doi: 10.1038/s41556-024-01358-2. Epub 2024 Feb 20.
4
Digital and manual interfollicular Ki-67 are associated with a progression-free survival in patients with low-grade follicular lymphoma.数字化和手动滤泡间 Ki-67 与低级别滤泡性淋巴瘤患者的无进展生存相关。
Am J Clin Pathol. 2024 Apr 3;161(4):380-387. doi: 10.1093/ajcp/aqad161.
5
The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma.预后指数PRIMA-PI联合Ki67能更好地预测滤泡性淋巴瘤在24个月内的疾病进展。
Front Oncol. 2023 Jun 23;13:1090610. doi: 10.3389/fonc.2023.1090610. eCollection 2023.
6
Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.评估滤泡性淋巴瘤一线免疫化疗的 4 种预后指标。
Blood Adv. 2023 Apr 25;7(8):1606-1614. doi: 10.1182/bloodadvances.2022007949.
7
Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.利用单细胞成像质谱流式细胞术揭示 24 个月内进展的滤泡性淋巴瘤患者肿瘤免疫微环境的演变。
J Hematol Oncol. 2022 Aug 22;15(1):115. doi: 10.1186/s13045-022-01326-z.
8
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.RELEVANCE 研究：来那度胺联合利妥昔单抗（R）对比利妥昔单抗-化疗后利妥昔单抗维持治疗未经治疗的晚期滤泡性淋巴瘤的 6 年结果。
J Clin Oncol. 2022 Oct 1;40(28):3239-3245. doi: 10.1200/JCO.22.00843. Epub 2022 Aug 10.
9
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.《世界卫生组织造血与淋巴组织肿瘤分类》第五版：淋巴肿瘤。
Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.
10
Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression.滤泡性淋巴瘤微环境特征与肿瘤细胞突变和 MHC Ⅱ类表达相关。
Blood Cancer Discov. 2022 Sep 6;3(5):428-443. doi: 10.1158/2643-3230.BCD-21-0075.